A Dose Block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase I Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of JW1601
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2019
Price : $35 *
At a glance
- Drugs JWP-1601 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 27 Aug 2019 Results of the single-dose phase of this study published in the LEO Pharma media release.
- 27 Aug 2019 According to a LEO Pharma media release, the company announced that the single-dose phase for this study has been completed with acceptable safety and tolerability observed up to the highest dose, 5th cohort.
- 10 Jul 2019 Status changed from planning to recruiting.